Connection

John O'Bryan to Neoplasms

Back to Details
This is a "connection" page, showing publications John O'Bryan has written about Neoplasms.
John O'Bryan
Connection Strength
2.026
Neoplasms
  1. Targeting the "undruggable" RAS with biologics. Adv Cancer Res. 2022; 153:237-266.
    View in: PubMed
    Score: 0.340
  2. Probing RAS Function with Monobodies. Methods Mol Biol. 2021; 2262:281-302.
    View in: PubMed
    Score: 0.326
  3. Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020 10 30; 48(5):1831-1841.
    View in: PubMed
    Score: 0.322
  4. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020; 148:69-146.
    View in: PubMed
    Score: 0.315
  5. Pharmacological targeting of RAS: Recent success with direct inhibitors. Pharmacol Res. 2019 01; 139:503-511.
    View in: PubMed
    Score: 0.280
  6. Direct inhibition of RAS: Quest for the Holy Grail? Semin Cancer Biol. 2019 02; 54:138-148.
    View in: PubMed
    Score: 0.264
  7. Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nat Commun. 2021 05 11; 12(1):2656.
    View in: PubMed
    Score: 0.083
  8. Therapeutic targeting of RAS: New hope for drugging the "undruggable". Biochim Biophys Acta Mol Cell Res. 2020 02; 1867(2):118570.
    View in: PubMed
    Score: 0.075
  9. Mitogenesis and endocytosis: What's at the INTERSECTIoN? Oncogene. 2001 Oct 01; 20(44):6300-8.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.